nodes	percent_of_prediction	percent_of_DWPC	metapath
Escitalopram—CYP2D6—breast cancer	0.16	0.538	CbGaD
Escitalopram—CYP3A4—breast cancer	0.138	0.462	CbGaD
Escitalopram—CYP2C19—Lapatinib—breast cancer	0.0313	0.0927	CbGbCtD
Escitalopram—CYP3A4—Exemestane—breast cancer	0.03	0.0887	CbGbCtD
Escitalopram—CYP2D6—Idarubicin—breast cancer	0.0271	0.0801	CbGbCtD
Escitalopram—CYP3A4—Letrozole—breast cancer	0.0255	0.0754	CbGbCtD
Escitalopram—CYP3A4—Anastrozole—breast cancer	0.0227	0.0672	CbGbCtD
Escitalopram—CYP3A4—Toremifene—breast cancer	0.0208	0.0615	CbGbCtD
Escitalopram—CYP3A4—Fulvestrant—breast cancer	0.0193	0.0571	CbGbCtD
Escitalopram—CYP3A4—Thiotepa—breast cancer	0.0172	0.0509	CbGbCtD
Escitalopram—CYP3A4—Ixabepilone—breast cancer	0.0157	0.0466	CbGbCtD
Escitalopram—CYP2C19—Tamoxifen—breast cancer	0.0157	0.0464	CbGbCtD
Escitalopram—CYP3A4—Lapatinib—breast cancer	0.0151	0.0448	CbGbCtD
Escitalopram—CYP2D6—Vinorelbine—breast cancer	0.0132	0.0391	CbGbCtD
Escitalopram—CYP2D6—Tamoxifen—breast cancer	0.0119	0.0353	CbGbCtD
Escitalopram—CYP3A4—Raloxifene—breast cancer	0.0115	0.034	CbGbCtD
Escitalopram—CYP3A4—Vinorelbine—breast cancer	0.0084	0.0249	CbGbCtD
Escitalopram—CYP2D6—Vinblastine—breast cancer	0.00814	0.0241	CbGbCtD
Escitalopram—CYP3A4—Tamoxifen—breast cancer	0.00759	0.0224	CbGbCtD
Escitalopram—CYP3A4—Mitoxantrone—breast cancer	0.0074	0.0219	CbGbCtD
Escitalopram—CYP3A4—Paclitaxel—breast cancer	0.0059	0.0175	CbGbCtD
Escitalopram—CYP3A4—Irinotecan—breast cancer	0.00582	0.0172	CbGbCtD
Escitalopram—CYP3A4—Vinblastine—breast cancer	0.00518	0.0153	CbGbCtD
Escitalopram—CYP2D6—Doxorubicin—breast cancer	0.005	0.0148	CbGbCtD
Escitalopram—CYP3A4—Docetaxel—breast cancer	0.00427	0.0126	CbGbCtD
Escitalopram—CYP3A4—Doxorubicin—breast cancer	0.00318	0.00942	CbGbCtD
Escitalopram—Citalopram—CYP2D6—breast cancer	0.00108	0.389	CrCbGaD
Escitalopram—Citalopram—CYP3A4—breast cancer	0.000923	0.333	CrCbGaD
Escitalopram—Citalopram—ABCB1—breast cancer	0.000769	0.278	CrCbGaD
Escitalopram—Urethral disorder—Doxorubicin—breast cancer	1.86e-05	6.61e-05	CcSEcCtD
Escitalopram—Nausea—Irinotecan—breast cancer	1.86e-05	6.6e-05	CcSEcCtD
Escitalopram—Nausea—Mitoxantrone—breast cancer	1.86e-05	6.6e-05	CcSEcCtD
Escitalopram—Immune system disorder—Epirubicin—breast cancer	1.85e-05	6.58e-05	CcSEcCtD
Escitalopram—Mediastinal disorder—Epirubicin—breast cancer	1.85e-05	6.57e-05	CcSEcCtD
Escitalopram—Pain—Docetaxel—breast cancer	1.85e-05	6.57e-05	CcSEcCtD
Escitalopram—Constipation—Docetaxel—breast cancer	1.85e-05	6.57e-05	CcSEcCtD
Escitalopram—Back pain—Methotrexate—breast cancer	1.85e-05	6.56e-05	CcSEcCtD
Escitalopram—Dyspepsia—Capecitabine—breast cancer	1.84e-05	6.54e-05	CcSEcCtD
Escitalopram—Chills—Epirubicin—breast cancer	1.84e-05	6.54e-05	CcSEcCtD
Escitalopram—Arrhythmia—Epirubicin—breast cancer	1.83e-05	6.51e-05	CcSEcCtD
Escitalopram—Visual impairment—Doxorubicin—breast cancer	1.83e-05	6.5e-05	CcSEcCtD
Escitalopram—Asthenia—Paclitaxel—breast cancer	1.83e-05	6.5e-05	CcSEcCtD
Escitalopram—Decreased appetite—Capecitabine—breast cancer	1.82e-05	6.46e-05	CcSEcCtD
Escitalopram—Alopecia—Epirubicin—breast cancer	1.81e-05	6.44e-05	CcSEcCtD
Escitalopram—Nausea—Gemcitabine—breast cancer	1.81e-05	6.43e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Capecitabine—breast cancer	1.81e-05	6.42e-05	CcSEcCtD
Escitalopram—Fatigue—Capecitabine—breast cancer	1.8e-05	6.41e-05	CcSEcCtD
Escitalopram—Pruritus—Paclitaxel—breast cancer	1.8e-05	6.41e-05	CcSEcCtD
Escitalopram—Vision blurred—Methotrexate—breast cancer	1.8e-05	6.39e-05	CcSEcCtD
Escitalopram—Mental disorder—Epirubicin—breast cancer	1.8e-05	6.39e-05	CcSEcCtD
Escitalopram—Erythema multiforme—Doxorubicin—breast cancer	1.8e-05	6.38e-05	CcSEcCtD
Escitalopram—Constipation—Capecitabine—breast cancer	1.79e-05	6.36e-05	CcSEcCtD
Escitalopram—Pain—Capecitabine—breast cancer	1.79e-05	6.36e-05	CcSEcCtD
Escitalopram—Erythema—Epirubicin—breast cancer	1.79e-05	6.35e-05	CcSEcCtD
Escitalopram—Malnutrition—Epirubicin—breast cancer	1.79e-05	6.35e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Docetaxel—breast cancer	1.78e-05	6.33e-05	CcSEcCtD
Escitalopram—Nausea—Fluorouracil—breast cancer	1.78e-05	6.32e-05	CcSEcCtD
Escitalopram—Eye disorder—Doxorubicin—breast cancer	1.77e-05	6.3e-05	CcSEcCtD
Escitalopram—Ill-defined disorder—Methotrexate—breast cancer	1.77e-05	6.29e-05	CcSEcCtD
Escitalopram—Tinnitus—Doxorubicin—breast cancer	1.77e-05	6.29e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Docetaxel—breast cancer	1.77e-05	6.28e-05	CcSEcCtD
Escitalopram—Anaemia—Methotrexate—breast cancer	1.76e-05	6.27e-05	CcSEcCtD
Escitalopram—Flushing—Doxorubicin—breast cancer	1.76e-05	6.26e-05	CcSEcCtD
Escitalopram—Cardiac disorder—Doxorubicin—breast cancer	1.76e-05	6.26e-05	CcSEcCtD
Escitalopram—Flatulence—Epirubicin—breast cancer	1.76e-05	6.25e-05	CcSEcCtD
Escitalopram—Tension—Epirubicin—breast cancer	1.75e-05	6.23e-05	CcSEcCtD
Escitalopram—Dysgeusia—Epirubicin—breast cancer	1.75e-05	6.21e-05	CcSEcCtD
Escitalopram—Diarrhoea—Paclitaxel—breast cancer	1.75e-05	6.2e-05	CcSEcCtD
Escitalopram—Nervousness—Epirubicin—breast cancer	1.74e-05	6.16e-05	CcSEcCtD
Escitalopram—Back pain—Epirubicin—breast cancer	1.73e-05	6.14e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Capecitabine—breast cancer	1.72e-05	6.13e-05	CcSEcCtD
Escitalopram—Angiopathy—Doxorubicin—breast cancer	1.72e-05	6.12e-05	CcSEcCtD
Escitalopram—Malaise—Methotrexate—breast cancer	1.72e-05	6.12e-05	CcSEcCtD
Escitalopram—Muscle spasms—Epirubicin—breast cancer	1.72e-05	6.1e-05	CcSEcCtD
Escitalopram—Immune system disorder—Doxorubicin—breast cancer	1.72e-05	6.09e-05	CcSEcCtD
Escitalopram—Vertigo—Methotrexate—breast cancer	1.72e-05	6.09e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Capecitabine—breast cancer	1.71e-05	6.08e-05	CcSEcCtD
Escitalopram—Mediastinal disorder—Doxorubicin—breast cancer	1.71e-05	6.08e-05	CcSEcCtD
Escitalopram—Body temperature increased—Docetaxel—breast cancer	1.71e-05	6.07e-05	CcSEcCtD
Escitalopram—Abdominal pain—Docetaxel—breast cancer	1.71e-05	6.07e-05	CcSEcCtD
Escitalopram—Leukopenia—Methotrexate—breast cancer	1.71e-05	6.07e-05	CcSEcCtD
Escitalopram—Chills—Doxorubicin—breast cancer	1.7e-05	6.05e-05	CcSEcCtD
Escitalopram—Arrhythmia—Doxorubicin—breast cancer	1.7e-05	6.03e-05	CcSEcCtD
Escitalopram—Dizziness—Paclitaxel—breast cancer	1.69e-05	5.99e-05	CcSEcCtD
Escitalopram—Vision blurred—Epirubicin—breast cancer	1.68e-05	5.98e-05	CcSEcCtD
Escitalopram—Alopecia—Doxorubicin—breast cancer	1.68e-05	5.96e-05	CcSEcCtD
Escitalopram—Cough—Methotrexate—breast cancer	1.67e-05	5.92e-05	CcSEcCtD
Escitalopram—Mental disorder—Doxorubicin—breast cancer	1.66e-05	5.91e-05	CcSEcCtD
Escitalopram—Urticaria—Capecitabine—breast cancer	1.66e-05	5.91e-05	CcSEcCtD
Escitalopram—Ill-defined disorder—Epirubicin—breast cancer	1.66e-05	5.89e-05	CcSEcCtD
Escitalopram—Abdominal pain—Capecitabine—breast cancer	1.65e-05	5.88e-05	CcSEcCtD
Escitalopram—Body temperature increased—Capecitabine—breast cancer	1.65e-05	5.88e-05	CcSEcCtD
Escitalopram—Convulsion—Methotrexate—breast cancer	1.65e-05	5.88e-05	CcSEcCtD
Escitalopram—Malnutrition—Doxorubicin—breast cancer	1.65e-05	5.87e-05	CcSEcCtD
Escitalopram—Erythema—Doxorubicin—breast cancer	1.65e-05	5.87e-05	CcSEcCtD
Escitalopram—Anaemia—Epirubicin—breast cancer	1.65e-05	5.87e-05	CcSEcCtD
Escitalopram—Agitation—Epirubicin—breast cancer	1.64e-05	5.83e-05	CcSEcCtD
Escitalopram—Flatulence—Doxorubicin—breast cancer	1.63e-05	5.79e-05	CcSEcCtD
Escitalopram—Myalgia—Methotrexate—breast cancer	1.63e-05	5.77e-05	CcSEcCtD
Escitalopram—Arthralgia—Methotrexate—breast cancer	1.63e-05	5.77e-05	CcSEcCtD
Escitalopram—Chest pain—Methotrexate—breast cancer	1.63e-05	5.77e-05	CcSEcCtD
Escitalopram—Tension—Doxorubicin—breast cancer	1.62e-05	5.76e-05	CcSEcCtD
Escitalopram—Vomiting—Paclitaxel—breast cancer	1.62e-05	5.76e-05	CcSEcCtD
Escitalopram—Dysgeusia—Doxorubicin—breast cancer	1.62e-05	5.75e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.61e-05	5.73e-05	CcSEcCtD
Escitalopram—Malaise—Epirubicin—breast cancer	1.61e-05	5.72e-05	CcSEcCtD
Escitalopram—Rash—Paclitaxel—breast cancer	1.61e-05	5.71e-05	CcSEcCtD
Escitalopram—Dermatitis—Paclitaxel—breast cancer	1.61e-05	5.71e-05	CcSEcCtD
Escitalopram—Discomfort—Methotrexate—breast cancer	1.61e-05	5.7e-05	CcSEcCtD
Escitalopram—Nervousness—Doxorubicin—breast cancer	1.61e-05	5.7e-05	CcSEcCtD
Escitalopram—Vertigo—Epirubicin—breast cancer	1.61e-05	5.7e-05	CcSEcCtD
Escitalopram—Syncope—Epirubicin—breast cancer	1.6e-05	5.69e-05	CcSEcCtD
Escitalopram—Leukopenia—Epirubicin—breast cancer	1.6e-05	5.68e-05	CcSEcCtD
Escitalopram—Back pain—Doxorubicin—breast cancer	1.6e-05	5.68e-05	CcSEcCtD
Escitalopram—Headache—Paclitaxel—breast cancer	1.6e-05	5.68e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Docetaxel—breast cancer	1.59e-05	5.66e-05	CcSEcCtD
Escitalopram—Muscle spasms—Doxorubicin—breast cancer	1.59e-05	5.65e-05	CcSEcCtD
Escitalopram—Palpitations—Epirubicin—breast cancer	1.58e-05	5.61e-05	CcSEcCtD
Escitalopram—Confusional state—Methotrexate—breast cancer	1.57e-05	5.58e-05	CcSEcCtD
Escitalopram—Loss of consciousness—Epirubicin—breast cancer	1.57e-05	5.58e-05	CcSEcCtD
Escitalopram—Cough—Epirubicin—breast cancer	1.56e-05	5.54e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Methotrexate—breast cancer	1.56e-05	5.53e-05	CcSEcCtD
Escitalopram—Vision blurred—Doxorubicin—breast cancer	1.56e-05	5.53e-05	CcSEcCtD
Escitalopram—Asthenia—Docetaxel—breast cancer	1.55e-05	5.51e-05	CcSEcCtD
Escitalopram—Convulsion—Epirubicin—breast cancer	1.55e-05	5.5e-05	CcSEcCtD
Escitalopram—Infection—Methotrexate—breast cancer	1.55e-05	5.5e-05	CcSEcCtD
Escitalopram—Hypertension—Epirubicin—breast cancer	1.54e-05	5.48e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Capecitabine—breast cancer	1.54e-05	5.48e-05	CcSEcCtD
Escitalopram—Ill-defined disorder—Doxorubicin—breast cancer	1.53e-05	5.45e-05	CcSEcCtD
Escitalopram—Pruritus—Docetaxel—breast cancer	1.53e-05	5.43e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Methotrexate—breast cancer	1.53e-05	5.43e-05	CcSEcCtD
Escitalopram—Anaemia—Doxorubicin—breast cancer	1.53e-05	5.43e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Methotrexate—breast cancer	1.53e-05	5.42e-05	CcSEcCtD
Escitalopram—Chest pain—Epirubicin—breast cancer	1.52e-05	5.4e-05	CcSEcCtD
Escitalopram—Arthralgia—Epirubicin—breast cancer	1.52e-05	5.4e-05	CcSEcCtD
Escitalopram—Myalgia—Epirubicin—breast cancer	1.52e-05	5.4e-05	CcSEcCtD
Escitalopram—Agitation—Doxorubicin—breast cancer	1.52e-05	5.4e-05	CcSEcCtD
Escitalopram—Anxiety—Epirubicin—breast cancer	1.52e-05	5.38e-05	CcSEcCtD
Escitalopram—Nausea—Paclitaxel—breast cancer	1.52e-05	5.38e-05	CcSEcCtD
Escitalopram—Skin disorder—Methotrexate—breast cancer	1.51e-05	5.38e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.51e-05	5.37e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Methotrexate—breast cancer	1.51e-05	5.35e-05	CcSEcCtD
Escitalopram—Discomfort—Epirubicin—breast cancer	1.5e-05	5.34e-05	CcSEcCtD
Escitalopram—Asthenia—Capecitabine—breast cancer	1.5e-05	5.33e-05	CcSEcCtD
Escitalopram—Malaise—Doxorubicin—breast cancer	1.49e-05	5.3e-05	CcSEcCtD
Escitalopram—Dry mouth—Epirubicin—breast cancer	1.49e-05	5.28e-05	CcSEcCtD
Escitalopram—Vertigo—Doxorubicin—breast cancer	1.49e-05	5.28e-05	CcSEcCtD
Escitalopram—Anorexia—Methotrexate—breast cancer	1.49e-05	5.28e-05	CcSEcCtD
Escitalopram—Syncope—Doxorubicin—breast cancer	1.48e-05	5.27e-05	CcSEcCtD
Escitalopram—Pruritus—Capecitabine—breast cancer	1.48e-05	5.26e-05	CcSEcCtD
Escitalopram—Leukopenia—Doxorubicin—breast cancer	1.48e-05	5.26e-05	CcSEcCtD
Escitalopram—Diarrhoea—Docetaxel—breast cancer	1.48e-05	5.25e-05	CcSEcCtD
Escitalopram—Confusional state—Epirubicin—breast cancer	1.47e-05	5.22e-05	CcSEcCtD
Escitalopram—Palpitations—Doxorubicin—breast cancer	1.46e-05	5.19e-05	CcSEcCtD
Escitalopram—Oedema—Epirubicin—breast cancer	1.46e-05	5.18e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Epirubicin—breast cancer	1.46e-05	5.18e-05	CcSEcCtD
Escitalopram—Hypotension—Methotrexate—breast cancer	1.46e-05	5.17e-05	CcSEcCtD
Escitalopram—Loss of consciousness—Doxorubicin—breast cancer	1.45e-05	5.16e-05	CcSEcCtD
Escitalopram—Infection—Epirubicin—breast cancer	1.45e-05	5.15e-05	CcSEcCtD
Escitalopram—Cough—Doxorubicin—breast cancer	1.44e-05	5.12e-05	CcSEcCtD
Escitalopram—Shock—Epirubicin—breast cancer	1.43e-05	5.1e-05	CcSEcCtD
Escitalopram—Convulsion—Doxorubicin—breast cancer	1.43e-05	5.09e-05	CcSEcCtD
Escitalopram—Diarrhoea—Capecitabine—breast cancer	1.43e-05	5.09e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Epirubicin—breast cancer	1.43e-05	5.08e-05	CcSEcCtD
Escitalopram—Dizziness—Docetaxel—breast cancer	1.43e-05	5.08e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Epirubicin—breast cancer	1.43e-05	5.07e-05	CcSEcCtD
Escitalopram—Hypertension—Doxorubicin—breast cancer	1.43e-05	5.07e-05	CcSEcCtD
Escitalopram—Tachycardia—Epirubicin—breast cancer	1.42e-05	5.05e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Methotrexate—breast cancer	1.42e-05	5.04e-05	CcSEcCtD
Escitalopram—Skin disorder—Epirubicin—breast cancer	1.42e-05	5.03e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Epirubicin—breast cancer	1.41e-05	5.01e-05	CcSEcCtD
Escitalopram—Insomnia—Methotrexate—breast cancer	1.41e-05	5.01e-05	CcSEcCtD
Escitalopram—Arthralgia—Doxorubicin—breast cancer	1.41e-05	5e-05	CcSEcCtD
Escitalopram—Myalgia—Doxorubicin—breast cancer	1.41e-05	5e-05	CcSEcCtD
Escitalopram—Chest pain—Doxorubicin—breast cancer	1.41e-05	5e-05	CcSEcCtD
Escitalopram—Anxiety—Doxorubicin—breast cancer	1.4e-05	4.98e-05	CcSEcCtD
Escitalopram—Paraesthesia—Methotrexate—breast cancer	1.4e-05	4.97e-05	CcSEcCtD
Escitalopram—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.4e-05	4.96e-05	CcSEcCtD
Escitalopram—Discomfort—Doxorubicin—breast cancer	1.39e-05	4.94e-05	CcSEcCtD
Escitalopram—Anorexia—Epirubicin—breast cancer	1.39e-05	4.94e-05	CcSEcCtD
Escitalopram—Dyspnoea—Methotrexate—breast cancer	1.39e-05	4.93e-05	CcSEcCtD
Escitalopram—Somnolence—Methotrexate—breast cancer	1.39e-05	4.92e-05	CcSEcCtD
Escitalopram—Dizziness—Capecitabine—breast cancer	1.38e-05	4.92e-05	CcSEcCtD
Escitalopram—Dry mouth—Doxorubicin—breast cancer	1.38e-05	4.89e-05	CcSEcCtD
Escitalopram—Vomiting—Docetaxel—breast cancer	1.37e-05	4.88e-05	CcSEcCtD
Escitalopram—Dyspepsia—Methotrexate—breast cancer	1.37e-05	4.87e-05	CcSEcCtD
Escitalopram—Rash—Docetaxel—breast cancer	1.36e-05	4.84e-05	CcSEcCtD
Escitalopram—Hypotension—Epirubicin—breast cancer	1.36e-05	4.84e-05	CcSEcCtD
Escitalopram—Dermatitis—Docetaxel—breast cancer	1.36e-05	4.84e-05	CcSEcCtD
Escitalopram—Confusional state—Doxorubicin—breast cancer	1.36e-05	4.83e-05	CcSEcCtD
Escitalopram—Decreased appetite—Methotrexate—breast cancer	1.35e-05	4.81e-05	CcSEcCtD
Escitalopram—Headache—Docetaxel—breast cancer	1.35e-05	4.81e-05	CcSEcCtD
Escitalopram—Oedema—Doxorubicin—breast cancer	1.35e-05	4.79e-05	CcSEcCtD
Escitalopram—Anaphylactic shock—Doxorubicin—breast cancer	1.35e-05	4.79e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Methotrexate—breast cancer	1.35e-05	4.78e-05	CcSEcCtD
Escitalopram—Fatigue—Methotrexate—breast cancer	1.34e-05	4.77e-05	CcSEcCtD
Escitalopram—Infection—Doxorubicin—breast cancer	1.34e-05	4.76e-05	CcSEcCtD
Escitalopram—Pain—Methotrexate—breast cancer	1.33e-05	4.73e-05	CcSEcCtD
Escitalopram—Vomiting—Capecitabine—breast cancer	1.33e-05	4.73e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Epirubicin—breast cancer	1.33e-05	4.72e-05	CcSEcCtD
Escitalopram—Shock—Doxorubicin—breast cancer	1.33e-05	4.71e-05	CcSEcCtD
Escitalopram—Nervous system disorder—Doxorubicin—breast cancer	1.32e-05	4.7e-05	CcSEcCtD
Escitalopram—Thrombocytopenia—Doxorubicin—breast cancer	1.32e-05	4.69e-05	CcSEcCtD
Escitalopram—Rash—Capecitabine—breast cancer	1.32e-05	4.69e-05	CcSEcCtD
Escitalopram—Insomnia—Epirubicin—breast cancer	1.32e-05	4.68e-05	CcSEcCtD
Escitalopram—Dermatitis—Capecitabine—breast cancer	1.32e-05	4.68e-05	CcSEcCtD
Escitalopram—Tachycardia—Doxorubicin—breast cancer	1.32e-05	4.68e-05	CcSEcCtD
Escitalopram—Headache—Capecitabine—breast cancer	1.31e-05	4.66e-05	CcSEcCtD
Escitalopram—Skin disorder—Doxorubicin—breast cancer	1.31e-05	4.65e-05	CcSEcCtD
Escitalopram—Paraesthesia—Epirubicin—breast cancer	1.31e-05	4.65e-05	CcSEcCtD
Escitalopram—Hyperhidrosis—Doxorubicin—breast cancer	1.3e-05	4.63e-05	CcSEcCtD
Escitalopram—Dyspnoea—Epirubicin—breast cancer	1.3e-05	4.62e-05	CcSEcCtD
Escitalopram—Somnolence—Epirubicin—breast cancer	1.3e-05	4.6e-05	CcSEcCtD
Escitalopram—Anorexia—Doxorubicin—breast cancer	1.29e-05	4.57e-05	CcSEcCtD
Escitalopram—Nausea—Docetaxel—breast cancer	1.28e-05	4.56e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Methotrexate—breast cancer	1.28e-05	4.56e-05	CcSEcCtD
Escitalopram—Dyspepsia—Epirubicin—breast cancer	1.28e-05	4.56e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Methotrexate—breast cancer	1.27e-05	4.53e-05	CcSEcCtD
Escitalopram—Decreased appetite—Epirubicin—breast cancer	1.27e-05	4.5e-05	CcSEcCtD
Escitalopram—Hypotension—Doxorubicin—breast cancer	1.26e-05	4.48e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Epirubicin—breast cancer	1.26e-05	4.47e-05	CcSEcCtD
Escitalopram—Fatigue—Epirubicin—breast cancer	1.26e-05	4.47e-05	CcSEcCtD
Escitalopram—Pain—Epirubicin—breast cancer	1.25e-05	4.43e-05	CcSEcCtD
Escitalopram—Constipation—Epirubicin—breast cancer	1.25e-05	4.43e-05	CcSEcCtD
Escitalopram—Nausea—Capecitabine—breast cancer	1.24e-05	4.42e-05	CcSEcCtD
Escitalopram—Urticaria—Methotrexate—breast cancer	1.24e-05	4.4e-05	CcSEcCtD
Escitalopram—Abdominal pain—Methotrexate—breast cancer	1.23e-05	4.38e-05	CcSEcCtD
Escitalopram—Body temperature increased—Methotrexate—breast cancer	1.23e-05	4.38e-05	CcSEcCtD
Escitalopram—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.23e-05	4.37e-05	CcSEcCtD
Escitalopram—Insomnia—Doxorubicin—breast cancer	1.22e-05	4.33e-05	CcSEcCtD
Escitalopram—Paraesthesia—Doxorubicin—breast cancer	1.21e-05	4.3e-05	CcSEcCtD
Escitalopram—Dyspnoea—Doxorubicin—breast cancer	1.2e-05	4.27e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Epirubicin—breast cancer	1.2e-05	4.27e-05	CcSEcCtD
Escitalopram—Somnolence—Doxorubicin—breast cancer	1.2e-05	4.26e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Epirubicin—breast cancer	1.19e-05	4.24e-05	CcSEcCtD
Escitalopram—Dyspepsia—Doxorubicin—breast cancer	1.19e-05	4.22e-05	CcSEcCtD
Escitalopram—Decreased appetite—Doxorubicin—breast cancer	1.17e-05	4.17e-05	CcSEcCtD
Escitalopram—Gastrointestinal disorder—Doxorubicin—breast cancer	1.16e-05	4.14e-05	CcSEcCtD
Escitalopram—Fatigue—Doxorubicin—breast cancer	1.16e-05	4.13e-05	CcSEcCtD
Escitalopram—Urticaria—Epirubicin—breast cancer	1.16e-05	4.11e-05	CcSEcCtD
Escitalopram—Constipation—Doxorubicin—breast cancer	1.15e-05	4.1e-05	CcSEcCtD
Escitalopram—Pain—Doxorubicin—breast cancer	1.15e-05	4.1e-05	CcSEcCtD
Escitalopram—Body temperature increased—Epirubicin—breast cancer	1.15e-05	4.09e-05	CcSEcCtD
Escitalopram—Abdominal pain—Epirubicin—breast cancer	1.15e-05	4.09e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Methotrexate—breast cancer	1.15e-05	4.08e-05	CcSEcCtD
Escitalopram—Asthenia—Methotrexate—breast cancer	1.12e-05	3.97e-05	CcSEcCtD
Escitalopram—Feeling abnormal—Doxorubicin—breast cancer	1.11e-05	3.95e-05	CcSEcCtD
Escitalopram—Gastrointestinal pain—Doxorubicin—breast cancer	1.1e-05	3.92e-05	CcSEcCtD
Escitalopram—Pruritus—Methotrexate—breast cancer	1.1e-05	3.92e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Epirubicin—breast cancer	1.07e-05	3.82e-05	CcSEcCtD
Escitalopram—Urticaria—Doxorubicin—breast cancer	1.07e-05	3.81e-05	CcSEcCtD
Escitalopram—Abdominal pain—Doxorubicin—breast cancer	1.07e-05	3.79e-05	CcSEcCtD
Escitalopram—Body temperature increased—Doxorubicin—breast cancer	1.07e-05	3.79e-05	CcSEcCtD
Escitalopram—Diarrhoea—Methotrexate—breast cancer	1.07e-05	3.79e-05	CcSEcCtD
Escitalopram—Asthenia—Epirubicin—breast cancer	1.05e-05	3.72e-05	CcSEcCtD
Escitalopram—Pruritus—Epirubicin—breast cancer	1.03e-05	3.66e-05	CcSEcCtD
Escitalopram—Dizziness—Methotrexate—breast cancer	1.03e-05	3.66e-05	CcSEcCtD
Escitalopram—Diarrhoea—Epirubicin—breast cancer	9.98e-06	3.54e-05	CcSEcCtD
Escitalopram—Hypersensitivity—Doxorubicin—breast cancer	9.94e-06	3.53e-05	CcSEcCtD
Escitalopram—Vomiting—Methotrexate—breast cancer	9.91e-06	3.52e-05	CcSEcCtD
Escitalopram—Rash—Methotrexate—breast cancer	9.82e-06	3.49e-05	CcSEcCtD
Escitalopram—Dermatitis—Methotrexate—breast cancer	9.82e-06	3.49e-05	CcSEcCtD
Escitalopram—Headache—Methotrexate—breast cancer	9.76e-06	3.47e-05	CcSEcCtD
Escitalopram—Asthenia—Doxorubicin—breast cancer	9.68e-06	3.44e-05	CcSEcCtD
Escitalopram—Dizziness—Epirubicin—breast cancer	9.64e-06	3.42e-05	CcSEcCtD
Escitalopram—Pruritus—Doxorubicin—breast cancer	9.55e-06	3.39e-05	CcSEcCtD
Escitalopram—Vomiting—Epirubicin—breast cancer	9.27e-06	3.29e-05	CcSEcCtD
Escitalopram—Nausea—Methotrexate—breast cancer	9.26e-06	3.29e-05	CcSEcCtD
Escitalopram—Diarrhoea—Doxorubicin—breast cancer	9.23e-06	3.28e-05	CcSEcCtD
Escitalopram—Rash—Epirubicin—breast cancer	9.19e-06	3.27e-05	CcSEcCtD
Escitalopram—Dermatitis—Epirubicin—breast cancer	9.19e-06	3.26e-05	CcSEcCtD
Escitalopram—Headache—Epirubicin—breast cancer	9.14e-06	3.24e-05	CcSEcCtD
Escitalopram—Dizziness—Doxorubicin—breast cancer	8.92e-06	3.17e-05	CcSEcCtD
Escitalopram—Nausea—Epirubicin—breast cancer	8.66e-06	3.08e-05	CcSEcCtD
Escitalopram—Vomiting—Doxorubicin—breast cancer	8.58e-06	3.05e-05	CcSEcCtD
Escitalopram—Rash—Doxorubicin—breast cancer	8.51e-06	3.02e-05	CcSEcCtD
Escitalopram—Dermatitis—Doxorubicin—breast cancer	8.5e-06	3.02e-05	CcSEcCtD
Escitalopram—Headache—Doxorubicin—breast cancer	8.45e-06	3e-05	CcSEcCtD
Escitalopram—Nausea—Doxorubicin—breast cancer	8.01e-06	2.85e-05	CcSEcCtD
Escitalopram—HRH1—Signaling Pathways—EGF—breast cancer	3.87e-06	4.86e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CYP1A1—breast cancer	3.86e-06	4.85e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ABCB1—breast cancer	3.86e-06	4.84e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGF—breast cancer	3.86e-06	4.84e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ACHE—breast cancer	3.84e-06	4.83e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTT1—breast cancer	3.84e-06	4.83e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	3.84e-06	4.82e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—APC—breast cancer	3.84e-06	4.82e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KIT—breast cancer	3.84e-06	4.82e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ERCC2—breast cancer	3.83e-06	4.81e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGF—breast cancer	3.8e-06	4.77e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—TYMS—breast cancer	3.79e-06	4.76e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—NOS3—breast cancer	3.75e-06	4.71e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—MAPK3—breast cancer	3.75e-06	4.71e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NCOR1—breast cancer	3.74e-06	4.7e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GSTM1—breast cancer	3.74e-06	4.7e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PLA2G4A—breast cancer	3.74e-06	4.7e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—MAPK3—breast cancer	3.74e-06	4.69e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—BRAF—breast cancer	3.68e-06	4.62e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	3.68e-06	4.62e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—BRAF—breast cancer	3.67e-06	4.6e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP17A1—breast cancer	3.64e-06	4.57e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—BRAF—breast cancer	3.61e-06	4.53e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ENO1—breast cancer	3.6e-06	4.52e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS1—breast cancer	3.6e-06	4.52e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—MTHFR—breast cancer	3.6e-06	4.52e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—GPX1—breast cancer	3.59e-06	4.5e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IGF1—breast cancer	3.58e-06	4.5e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT2—breast cancer	3.58e-06	4.5e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IGF1—breast cancer	3.57e-06	4.49e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—PIK3CA—breast cancer	3.57e-06	4.49e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT2—breast cancer	3.57e-06	4.48e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—EGFR—breast cancer	3.57e-06	4.48e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MDM2—breast cancer	3.56e-06	4.47e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—EGFR—breast cancer	3.55e-06	4.46e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CYP1A1—breast cancer	3.55e-06	4.46e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RAF1—breast cancer	3.54e-06	4.45e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP2D6—breast cancer	3.53e-06	4.44e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—RELA—breast cancer	3.53e-06	4.43e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ERCC2—breast cancer	3.52e-06	4.42e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IGF1—breast cancer	3.52e-06	4.42e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT2—breast cancer	3.51e-06	4.41e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—ERBB2—breast cancer	3.51e-06	4.4e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—EGFR—breast cancer	3.5e-06	4.39e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOA2—breast cancer	3.47e-06	4.35e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MTOR—breast cancer	3.46e-06	4.35e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CB—breast cancer	3.46e-06	4.35e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CD—breast cancer	3.44e-06	4.32e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CD—breast cancer	3.43e-06	4.31e-05	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—PIK3CA—breast cancer	3.41e-06	4.28e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SERPINE1—breast cancer	3.4e-06	4.27e-05	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	3.4e-06	4.27e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SERPINE1—breast cancer	3.39e-06	4.26e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	3.38e-06	4.24e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—KRAS—breast cancer	3.37e-06	4.23e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—FASN—breast cancer	3.36e-06	4.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—KRAS—breast cancer	3.36e-06	4.22e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—BCHE—breast cancer	3.35e-06	4.21e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	3.34e-06	4.2e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	3.34e-06	4.19e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CXCL8—breast cancer	3.33e-06	4.18e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—CAV1—breast cancer	3.32e-06	4.17e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—MTHFR—breast cancer	3.31e-06	4.16e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC5A5—breast cancer	3.31e-06	4.15e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—KRAS—breast cancer	3.31e-06	4.15e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—HRAS—breast cancer	3.3e-06	4.15e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—NOS3—breast cancer	3.25e-06	4.08e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1B—breast cancer	3.25e-06	4.08e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—NOS3—breast cancer	3.24e-06	4.07e-05	CbGpPWpGaD
Escitalopram—HTR2C—GPCR downstream signaling—AKT1—breast cancer	3.21e-06	4.03e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NQO1—breast cancer	3.19e-06	4.01e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—SLC2A1—breast cancer	3.19e-06	4.01e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—NOS3—breast cancer	3.19e-06	4e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CASP3—breast cancer	3.18e-06	4e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL2—breast cancer	3.18e-06	3.99e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	3.17e-06	3.98e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—IL6—breast cancer	3.16e-06	3.97e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CCND1—breast cancer	3.1e-06	3.89e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—PIK3CA—breast cancer	3.09e-06	3.89e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—JUN—breast cancer	3.09e-06	3.88e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	3.08e-06	3.87e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MDM2—breast cancer	3.08e-06	3.87e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MDM2—breast cancer	3.07e-06	3.86e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RAF1—breast cancer	3.07e-06	3.86e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CTNNB1—breast cancer	3.07e-06	3.85e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1B1—breast cancer	3.06e-06	3.85e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RAF1—breast cancer	3.06e-06	3.84e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—RELA—breast cancer	3.06e-06	3.84e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—CAV1—breast cancer	3.05e-06	3.83e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—RELA—breast cancer	3.05e-06	3.83e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—ERBB2—breast cancer	3.04e-06	3.82e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	3.04e-06	3.81e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—ERBB2—breast cancer	3.03e-06	3.8e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MDM2—breast cancer	3.02e-06	3.8e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CG—breast cancer	3.02e-06	3.8e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RAF1—breast cancer	3.01e-06	3.79e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MMP9—breast cancer	3.01e-06	3.78e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HSP90AA1—breast cancer	3e-06	3.77e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—RELA—breast cancer	3e-06	3.77e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MTOR—breast cancer	3e-06	3.77e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CB—breast cancer	3e-06	3.77e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—CDKN1A—breast cancer	3e-06	3.76e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PTEN—breast cancer	2.99e-06	3.76e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MTOR—breast cancer	2.99e-06	3.75e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CB—breast cancer	2.99e-06	3.75e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—ERBB2—breast cancer	2.98e-06	3.74e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MTOR—breast cancer	2.94e-06	3.7e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	2.94e-06	3.7e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK8—breast cancer	2.93e-06	3.67e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOA1—breast cancer	2.92e-06	3.67e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling by GPCR—AKT1—breast cancer	2.92e-06	3.66e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CXCL8—breast cancer	2.88e-06	3.62e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—STK11—breast cancer	2.88e-06	3.62e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP19A1—breast cancer	2.88e-06	3.62e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CXCL8—breast cancer	2.87e-06	3.61e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—HRAS—breast cancer	2.86e-06	3.6e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—HRAS—breast cancer	2.85e-06	3.58e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CXCL8—breast cancer	2.83e-06	3.55e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1B—breast cancer	2.81e-06	3.53e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—HRAS—breast cancer	2.81e-06	3.53e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1B—breast cancer	2.81e-06	3.52e-05	CbGpPWpGaD
Escitalopram—HRH1—GPCR downstream signaling—AKT1—breast cancer	2.78e-06	3.5e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CG—breast cancer	2.78e-06	3.49e-05	CbGpPWpGaD
Escitalopram—CHRM1—GPCR downstream signaling—AKT1—breast cancer	2.78e-06	3.48e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—SRC—breast cancer	2.77e-06	3.48e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	2.76e-06	3.47e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CASP3—breast cancer	2.76e-06	3.46e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL2—breast cancer	2.75e-06	3.46e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CASP3—breast cancer	2.75e-06	3.45e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL2—breast cancer	2.75e-06	3.45e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—IL6—breast cancer	2.74e-06	3.44e-05	CbGpPWpGaD
Escitalopram—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	2.73e-06	3.43e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—IL6—breast cancer	2.73e-06	3.43e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CASP3—breast cancer	2.71e-06	3.4e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL2—breast cancer	2.7e-06	3.39e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—VEGFA—breast cancer	2.7e-06	3.39e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—IL6—breast cancer	2.69e-06	3.38e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CCND1—breast cancer	2.68e-06	3.37e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—JUN—breast cancer	2.68e-06	3.36e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—COMT—breast cancer	2.68e-06	3.36e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CCND1—breast cancer	2.68e-06	3.36e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—STAT3—breast cancer	2.67e-06	3.36e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—JUN—breast cancer	2.67e-06	3.35e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTP1—breast cancer	2.66e-06	3.35e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CTNNB1—breast cancer	2.66e-06	3.34e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CD—breast cancer	2.66e-06	3.34e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CTNNB1—breast cancer	2.65e-06	3.33e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CCND1—breast cancer	2.63e-06	3.31e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—JUN—breast cancer	2.63e-06	3.3e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—HMOX1—breast cancer	2.63e-06	3.3e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—ALB—breast cancer	2.62e-06	3.29e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ITPR1—breast cancer	2.62e-06	3.29e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	2.61e-06	3.28e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MMP9—breast cancer	2.61e-06	3.27e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MMP9—breast cancer	2.6e-06	3.26e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—CDKN1A—breast cancer	2.6e-06	3.26e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PTEN—breast cancer	2.59e-06	3.25e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—CDKN1A—breast cancer	2.59e-06	3.25e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PTEN—breast cancer	2.58e-06	3.24e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MMP9—breast cancer	2.56e-06	3.21e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MAPK3—breast cancer	2.56e-06	3.21e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	2.55e-06	3.2e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PTEN—breast cancer	2.54e-06	3.19e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK8—breast cancer	2.54e-06	3.18e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling by GPCR—AKT1—breast cancer	2.53e-06	3.17e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK8—breast cancer	2.53e-06	3.17e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ABCB1—breast cancer	2.52e-06	3.17e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling by GPCR—AKT1—breast cancer	2.52e-06	3.16e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—NOS3—breast cancer	2.51e-06	3.15e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK8—breast cancer	2.49e-06	3.12e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—MYC—breast cancer	2.49e-06	3.12e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling by GPCR—AKT1—breast cancer	2.48e-06	3.12e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TGFB1—breast cancer	2.48e-06	3.11e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—TYMS—breast cancer	2.48e-06	3.11e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GSTM1—breast cancer	2.45e-06	3.07e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PLA2G4A—breast cancer	2.45e-06	3.07e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NCOR1—breast cancer	2.45e-06	3.07e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CD—breast cancer	2.44e-06	3.07e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—EGFR—breast cancer	2.43e-06	3.05e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—ALB—breast cancer	2.41e-06	3.03e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—SRC—breast cancer	2.4e-06	3.02e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—SRC—breast cancer	2.4e-06	3.01e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—SRC—breast cancer	2.36e-06	2.96e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—GPX1—breast cancer	2.34e-06	2.94e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—VEGFA—breast cancer	2.34e-06	2.94e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—VEGFA—breast cancer	2.33e-06	2.93e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CYP1A1—breast cancer	2.32e-06	2.91e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—STAT3—breast cancer	2.32e-06	2.91e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CB—breast cancer	2.32e-06	2.91e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—STAT3—breast cancer	2.31e-06	2.9e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—NOS3—breast cancer	2.31e-06	2.9e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ERCC2—breast cancer	2.3e-06	2.89e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—VEGFA—breast cancer	2.3e-06	2.88e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—KRAS—breast cancer	2.3e-06	2.88e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTGS2—breast cancer	2.3e-06	2.88e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—STAT3—breast cancer	2.27e-06	2.86e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MAPK3—breast cancer	2.21e-06	2.78e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MAPK3—breast cancer	2.21e-06	2.77e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MAPK3—breast cancer	2.17e-06	2.73e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—MTHFR—breast cancer	2.16e-06	2.72e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—MYC—breast cancer	2.15e-06	2.7e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TGFB1—breast cancer	2.15e-06	2.7e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—MYC—breast cancer	2.15e-06	2.7e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TGFB1—breast cancer	2.14e-06	2.69e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CB—breast cancer	2.13e-06	2.68e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—MYC—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTGS2—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—PIK3CA—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TGFB1—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—EGFR—breast cancer	2.11e-06	2.65e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—EGFR—breast cancer	2.1e-06	2.64e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—EGFR—breast cancer	2.07e-06	2.6e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—TP53—breast cancer	2.04e-06	2.56e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PTEN—breast cancer	2e-06	2.51e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—CAV1—breast cancer	2e-06	2.51e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—KRAS—breast cancer	1.99e-06	2.5e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—KRAS—breast cancer	1.98e-06	2.49e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.95e-06	2.45e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—HRAS—breast cancer	1.95e-06	2.45e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—IL6—breast cancer	1.87e-06	2.35e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PTEN—breast cancer	1.84e-06	2.31e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—PIK3CA—breast cancer	1.83e-06	2.3e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—PIK3CA—breast cancer	1.82e-06	2.29e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CG—breast cancer	1.82e-06	2.28e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.79e-06	2.25e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—TP53—breast cancer	1.77e-06	2.22e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—TP53—breast cancer	1.76e-06	2.21e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—TP53—breast cancer	1.74e-06	2.18e-05	CbGpPWpGaD
Escitalopram—HTR2C—Signaling Pathways—AKT1—breast cancer	1.72e-06	2.16e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—HRAS—breast cancer	1.69e-06	2.12e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—HRAS—breast cancer	1.69e-06	2.12e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.66e-06	2.08e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—IL6—breast cancer	1.62e-06	2.03e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—IL6—breast cancer	1.61e-06	2.03e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CD—breast cancer	1.6e-06	2.01e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—IL6—breast cancer	1.59e-06	1.99e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—ALB—breast cancer	1.58e-06	1.98e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—NOS3—breast cancer	1.51e-06	1.9e-05	CbGpPWpGaD
Escitalopram—HRH1—Signaling Pathways—AKT1—breast cancer	1.49e-06	1.88e-05	CbGpPWpGaD
Escitalopram—CHRM1—Signaling Pathways—AKT1—breast cancer	1.49e-06	1.87e-05	CbGpPWpGaD
Escitalopram—ADRA1A—Signaling Pathways—AKT1—breast cancer	1.47e-06	1.84e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—PIK3CA—breast cancer	1.41e-06	1.77e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CB—breast cancer	1.39e-06	1.75e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTGS2—breast cancer	1.38e-06	1.73e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—PIK3CA—breast cancer	1.3e-06	1.63e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PTEN—breast cancer	1.2e-06	1.51e-05	CbGpPWpGaD
Escitalopram—CYP2C19—Metabolism—AKT1—breast cancer	1.15e-06	1.45e-05	CbGpPWpGaD
Escitalopram—CYP2D6—Metabolism—AKT1—breast cancer	1.06e-06	1.33e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—PIK3CA—breast cancer	8.49e-07	1.07e-05	CbGpPWpGaD
Escitalopram—CYP3A4—Metabolism—AKT1—breast cancer	6.94e-07	8.71e-06	CbGpPWpGaD
